Immix Biopharma, Inc.

Contributing Author

Recent Articles by Immix Biopharma, Inc.

May-23	Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 IMMX -17.43% GlobeNewswire
May-22	Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis IMMX GlobeNewswire
May-21	Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis IMMX GlobeNewswire